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1. Introduction
   Nucleophosmin 1 (NPM1), one of the isoforms of NPM 
protein (also known as B23, numatrin or NO38), is a protein 
that shuttles between the nucleus and cytoplasm found at 
high levels in the granular regions of the nucleolus[1,2]. Many 
findings have revealed a complex scenario of NPM1 functions 
and interactions. Some main functions have been ascribed 
to NPM1: 1) promoting the biogenesis of the ribosome by 
acting as a chaperone that carries pre-ribosomal particles 
from the nucleolus to the cytoplasm and by facilitating 
the processing and maturation of ribosome RNA[1,3]; 2) 
controlling the duplication of the centrosome during the 
cell cycle[4]; 3) modulating the function of tumor-suppressor 
transcription factors, such as interferon regulatory factor 1 
(IRF-1) and p53[5]; and regulating the function and stability 
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of the p19ARF tumor suppressor[6] and the apoptosis[7].
   NPM1 is an essential protein, since the inactivation of the 
gene encoding for NPM1 in the mouse germ line leads to 
developmental defects that cause embryonic death in mid-
gestation[8]. In humans, accumulating evidences suggest 
that NPM1 is directly implicated in the pathogenesis of 
cancer. NPM1 is over-expressed in solid tumors of diverse 
histological origin or is involved in tumor progression[9,10]. 
In several hematologic malignancies, the NPM1 locus is lost 
or translocated leading to the formation of oncogenic fusion 
proteins[11]. Moreover, NPM1 is mutated in about one-third 
of adult patients with acute myeloid leukemia (AML), which 
makes NPM1 mutations the most frequent genetic lesions so 
far that identified in de novo AML[12].
   Mutations of NPM1 in AML disrupt the nucleolar-
localization signal, causing accumulation of NPM1 in the 
cytoplasm. AML with mutated NPM1 is generally characterized 
by good response to induction chemotherapy[13] and 
favorable prognosis (in the absence of a concomitant FLT3-
ITD mutation)[14,15]. However, a significant number of 
cases with NPM1-mutated AML still show poor outcome, 
especially those associated with FLT3-ITD mutation and 
elderly patients. Currently, some possible approaches on 
the development of a targeted therapy for NPM1-mutated 
AML were attributed, which including: 1) interfering with the 
aberrant transport of the NPM1 leukemic mutant; 2) inhibiting 
the capability of the residual wild-type nucleophosmin 
and other nucleolar components to act as hub proteins 
for assemblement of the nucleolus; and 3) intervening on 
minimal residual disease (NPM1 mutant copy transcripts) 
before overt hematological relapse occurs (so-called pre-
emptive therapy). Evaluating the activity of epigenetic drugs 
(e.g. 5-azacytidine) or agents acting on differentiation and 
apoptosis in NPM1-mutated AML is also warranted[14].
   In this paper, we have demonstrated that epigallocatechin-
3-gallate (EGCG) can down-regulate the expression of NPM1 
in IMS-M2 cells harboring the NPM1 mutations. Moreover, 
EGCG also suppressed the cell proliferation and induced 
apoptosis in IMS-M2 cells. We suggested that EGCG could be 
considered as a reagent for treatment of AML patients with 
NPM1 mutations.
2. Materials and methods
2.1. Cell lines and culture conditions
   IMS-M2 cells have been described previously[16]. Briefly, 
IMS-M2 was established from the bone marrow cells taken 
from a 59-year-old patient with AML (FAB M2), chromosome 
abnormalities of 48, XX, add (6) (q27), +8, inv(12) (p13q15), add 
(15) (q25), +add (15) (q25). This cell line harbors the mutation 
of NPM1 gene and the fusion of ETV6 to neurotrophin-3 
receptor TRKC[16]. A leukemic cell lines MOLM13[17] with NPM1 
wild-type[18] was used as control.
   The cells were grown in RPMI 1640 medium (Sigma-Aldrich, 
Japan K.K., Tokyo, Japan) supplemented with 10% heat-
inactivated fetal bovine serum (JRH Biosciences, Lenexa, 
KS, USA), 100 IU/mL penicillin, and 0.1 mg/mL streptomycin 
(Nakalai Tesque, Kyoto, Japan) in a humidified incubator of 
5% CO2 at 37 °C.
2.2. Reagents
   A purified powder of EGCG was generously gifted 
by Dr. Yukihiko Hara (Japan). EGCG was dissolved in 
dimethylsulfoxide (DMSO) (Wako Pure. Chemical Industries, 
Osaka, Japan). Controlled cells were cultured with the same 
concentration of carrier DMSO as used in the highest dose 
of reagents. The concentration of DMSO was kept under 0.1% 
throughout all the experiments to avoid its cytotoxicity.
2.3. Cell proliferation assays 
   Cell proliferation was determined by trypan blue dye 
exclusion test as described previously[17]. Briefly, cells were 
seeded in 6-well plates at a density of 1伊105 cells/mL in 
the presence of different concentrations of EGCG for 48 h. 
After the treatment, 10 µL of the cell suspension was mixed 
with 10 µL of 0.4% trypan blue, and alive cells were counted 
manually using a hemacytometer. Results were calculated 
as the percentage of the values measured when cells were 
grown in the absence of EGCG.
2.4. Morphologic assessment to detect apoptotic cells
   For detecting fragmented nuclei and condensed chromatin, 
cells at a density of 1伊105 cells/mL were treated with 
reagents. After indicated durations, cells were harvested 
and fixed onto slides by using a cytospin (Shandon, Shandon 
Southern Products Ltd., Cheshire, UK). Cells then were 
stained with Wright-Giemsa solution. Morphology of cells 
was observed under an inverted microscope.
2.5. Western blot analysis
   Cells were plated onto 10 cm dishes at a density of 1伊
10
5 cells/mL in the presence of various concentrations of 
EGCG. After incubation for indicated durations, cells were 
collected and washed twice with PBS (-). Cells were then 
dissolved in a protein lysis buffer containing 5 mmol/L EDTA, 
50 mmol/L NaF, 10 mmol/L Na2H2P2O7, 0.01% Triton X-100, 5 
mmol/L HEPES, 150 mmol/L NaCl, 1 mmol/L Na3VO4, 1 mmol/
L phenylmethylsulfonyl fluoride, and 75 µg/mL aprotinin 
on ice for 30 min with brief vortex of 4 times every 10 min. 
After centrifugation at 13 000 r/min at 4 °C for 10 min, total 
cell lysates were collected for western blot analysis. Protein 
samples were electrophoresed through a polyacrylamide 
gel and transferred to a Hypond-P membrane (Amersham, 
Buckinghamshire, UK) by electro-blotting. After washing, 
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the membrane was probed with antibodies and antibody-
binding was detected using enhanced chemiluminescence 
ECL (Amersham). The following antibodies were obtained 
from Santa Cruz Biotechnology (Santa Cruz, CA, USA): total 
Akt (sc-1618), anti-rabbit IgG-HRP (sc-2317) and anti-mouse 
IgG-HRP (sc-2031). Anti-actin (A2066) was from Sigma-
Aldrich. Phospho-Akt (Ser473), caspase-3 and NPM antibody 
were from Cell Signaling Technology Japan (Tokyo, Japan). 
Anti-PARP antibody was from WAKO Chemicals (Osaka, 
Japan).
2.6. Statistical analysis
   All datas were expressed as the mean依SD. Statistical 
analyses were done using Student’s t-test, in which P<0.05 
was the minimum requirement for a statistically significant 
difference.
3. Results
3.1. Growth-inhibitory effect of EGCG on IMS-M2 cells
   First, to test on growth-inhibitory effect of EGCG, IMS-
M2 cells were incubated either with the carrier DMSO alone 
(0 µmol/L EGCG) or with 5, 10, 20, 40 or 80 µmol/L EGCG for 
48 h. Cell proliferation was evaluated using the trypan 
blue exclusion test. The effect of EGCG on cell growth has 
been demonstrated in various cancers. In IMS-M2 cells, the 
percent of cell proliferation showed that EGCG suppressed 
the cell growth of IMS-M2 (Figure 1). The effect of EGCG on 
IMS-M2 cells is dependent on cell density as coincide with 
the results observed in GIST cell lines[19]. At a density of 1
伊105 cells/mL and 1伊104 cells/mL, IC50 of EGCG was around 
20 and 5 µmol/L, respectively (Figure 1). The cell growth 
inhibition by EGCG diminished dramatically with increasing 
cell densities, similar to phenomena reported in colorectal 
carcinoma cells and GIST cell[19]. 
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Figure 1. Effect of EGCG on cell proliferation of IMS-M2 cells. 
IMS-M2 cells at a density of 1伊105 cells/mL or 1伊104 cells/mL were treated 
with 5, 10, 20 or 40 µmol/L EGCG or DMSO alone (0 µmol/L EGCG) as control 
for 48 h. The number of alive cells was counted after trypan blue exclusion 
test. Results were calculated as the percentage of the control values.
3.2. Down-regulation of NPM1 in EGCG-treated IMS-M2 cells
   Next, we checked whether EGCG can affect on expression 
status of NPM1 protein. IMS-M2 cells were treated with different 
concentration of EGCG. After 8 h, the cells were harvested 
and extracted and then total cell lysates were subjected 
to western blot analysis. Interestingly, the expression of 
NPM1 was suppressed in EGCG-treated IMS-M2 cells in 
dose-dependent manner (Figure 2A). The time course was 
performed with the EGCG concentration and fixed at 60 µmol/
L for 3 and 8 h. The results shown that EGCG also inhibited 
the NPM1 expression in a time dependent manner (Figure 2B). 
Moreover, exposing MOLM13 cells that harboring wild-type 
NPM1 to different concentration of EGCG revealed that EGCG 
could not inhibited the expression of NPM1 (Figure 2C).
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Figure 2. Down-regulation of NPM1 expression in FLT3-mutated cells. 
Panel A and B showed the results of down-regulation of NPM1 expression by 
EGCG treatment in IMS-M2 cells as well as MOLM13 control cells shown in 
Panel C. The cells at a density of 1伊105 cells/ml were treated with 15, 30, or 60 
µmol/L EGCG or DMSO alone (0 µmol/L EGCG) as control for 8 h (A and C) or 
treated with 60 µmol/L EGCG for an indicated duration (B). Total cell lysates 
were subjected to western blot analysis with indicated antibodies. 
   Taken together, our data indicated that EGCG suppressed the 
cell proliferation of IMS-M2 cells through specific inhibited on 
NPM1 mutation. 
3.3. EGCG suppressed AKT activity in IMS-M2 cells
   It has been shown that constitutively active AKT protect cells 
from apoptosis. To clarify whether AKT were affected by EGCG 
in IMS-M2 cells, the activity of AKT in IMS-M2 cells treated with 
or without EGCG was meadured following the indicated duration 
as shown in Figure 3A. Western blot analysis using anti-
phosphospecific-Akt antibody showed that EGCG suppressed 
AKT phosphorylation in a time dependent manner (Figure 3A). 
That means EGCG could induce cell death in IMS-M2 cells.
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Figure 3. EGCG inhibited AKT activity and induce apoptosis in FLT3-mutated cells. 
Panel A showed the inhibitory effect of EGCG on AKT activity in IMS-M2 cells. 
IMS-M2 cells at a density of 1伊105 cells/ml were treated with 60 µmol/L EGCG or 
DMSO alone (0 µmol/L EGCG) as control for an indicated duration. Total cell lysates 
were subjected to western blot analysis with indicated antibodies. Panel B and C 
showed the evidences of apoptosis induced by EGCG treatment in IMS-M2 cells. The 
activation forms of caspase-3 and inactivation form of PARP were detected after 8 h 
treated with 60 µmol/L EGCG (B). The morphology of IMS-M2 cells after treated with 
or without EGCG were evaluated. After 8 h treated with 60 µmol/L EGCG, cells were 
fixed onto slides and stained with Wright-Giemsa solution. The arrow indicated 
that the nuclei of IMS-M2 cells were fragmented by EGCG treatment (C). 
3.4. EGCG induced apoptosis in IMS-M2 cells
   AKT involved in apoptosis has been clarified. In these cells, 
AKT phoshorylation was inhibited by EGCG treatment (Figure 
3A). To test whether EGCG induced apoptosis in IMS-M2 
cells, the cell morphology and the status of some apoptotic 
markers in IMS-M2 cells were checked after the treatment 
with EGCG. As a result, after 8 h treatment with 60 µmol/L 
EGCG, cleaved caspase-3 were detected, then inactivated one 
enzyme involved in DNA repair, PARP were detected (Figure 
3B). Caspase-3 proteolytic cleavage of PARP is a key event in 
apoptosis. In addition, the observed apoptotic bodies after 60 
µmol/L EGCG treatment (Figure 3C) indicated that EGCG caused 
apoptosis in IMS-M2 cell line harboring NPM1 mutations. 
4. Discussion
   As mentioned above, one of the potential strategies 
for treating AML patients with NPM1 mutation is finding 
any reagents that can enhance the propensity of NPM1-
mutated AML cells to die or to be killed[12]. In this study, we 
demonstrated that EGCG inhibited the cell proliferation and 
induced apoptosis in IMS-M2 cell line with NPM1 mutation 
and suggested that EGCG could be a potential reagent for 
treating AML patients harboring NPM1 mutation.
   AML with mutant NPM1 accounts for approximately one-
third of all AMLs. Because of its distinctive molecular, 
pathologic, immunophenotypic and clinical characteristics 
[13,20], NPM1-mutated AML has been included as a provisional 
entity in the 2008 World Health Organization classification 
of lympho-hemopoietic neoplasms. Despite the advantages 
of understanding about the role of NPM1 in leukegenesis, the 
development of a targeted therapy for NPM1-mutated AML has 
still been a problem. For a long time, the predominant abnormal 
accumulation of NPM1 mutant in cytoplasm attracted the 
scientists’ concern in finding drugs that can redirect NPM1 from 
cytoplasm to nucleus. However, it is very difficult to intervene on 
the abnormal traffic of the NPM1 mutant[20]. Leptomycin B is such 
a typical example, it can redirect NPM1 mutant to nucleoplasm 
but cannot direct to nucleolus (the physiological site of NPM1)
[12]. Currently, Balusu et al. suggested another direction, that 
is, to interfere on the level or the oligomerization status of NPM1 
that influence its capability to properly build up the nucleolus 
in NPM1-mutated AML cells[21]. Agreement with Balusu et al., 
we suggested that finding any reagents that can reduce or even 
completely inhibit the expression of NPM1 in AML with NPM1 
mutation leading to instability of nucleolus could be consider as 
potential strategies for treating AML with NPM1 mutation. 
   EGCG, the major polyphenol of green tea, has been used as 
a beverage for over 5 000 years. EGCG offers several potential 
clinical advantages compared to other traditional cancer 
drugs. Most modern medicines currently available for treating 
cancers are very expensive, while EGCG is globally available as 
tea, inexpensive to isolate and can be administered orally[22]. 
In addition, traditional cancer drugs that often destroy some 
healthy cells along with cancerous cells, while EGCG was 
noticed as an apoptosis inducer agent that is non-toxic to 
healthy cells[17,19,22,23]. Moreover, EGCG appears to target 
biochemical and genetic functions unique to cancer cells[17,22]. 
In this report we have shown that EGCG specifically targeted 
on NPM1 expression in IMS-M2 cells, but not in MOLM13 cells 
that carrying NPM1 wild-type. Some of the anti-carcinogenic 
agents currently in use have toxic adverse effects. However, 
data from clinical trials reported to date suggests that EGCG 
has a very acceptable safety profile[24]. It is noted that green 
tea is now developing as a cancer preventive drug in the USA 
and Europe[25]. Currently, there are 83 ongoing clinical trials 
studying the effects of EGCG on different pathologies[26]. These 
benefits support further development of EGCG as a potentially 
useful anti-carcinogenic agent.
   AML patients harboring mutant NPM1 often carry FLT3 
mutations, particularly the ITD-type mutations and poor 
prognosis[14]. In another paper, we have also demonstrated 
that EGCG could down-regulate the expression of FLT3 in 
FLT3 mutated cell lines (not yet published data) suggesting 
that EGCG can be a potential reagent for treating AML patients 
harboring NPM1 /FLT3 mutation.
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Comments 
Background
   This is a good work and very informative that the author 
evaluated the down-regulated expression of NPM1 in IMS-
M2 cell line by EGCG. Moreover, EGCG also suppressed the 
cell proliferation and induced apoptosis in IMS-M2 cells. In 
this study, the authors have suggested that EGCG could be 
considered as a reagent for treatment of AML patients with 
NPM1 mutations.
Research frontiers
   Studies are being performed in order to determine the 
effect of EGCG on Down-regulated expression of NPM1 in 
IMS-M2 Cell line.
Related reports
   There are very limited reports on related to this study. But 
the authors have developed a good technique for a treatment 
of AML using EGCG.
Innovations and breakthroughs
   In this study, the authors have evaluated the effect of EGCG 
for treatment of AML.
Applications
   This study is very useful for treatment of AML patients.
Peer review
   This is a good and useful study in which the authors have 
evaluated the down-regulated expression of NPM1 in IMS-M2 
cell line by EGCG. The results obtained in this work clearly 
suggested that EGCG was good for the treatment of AML patients. 
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